Mutations in several known or putative glycosyltransferases cause glycosylation defects in a-dystroglycan (a-DG), an integral component of the dystrophin glycoprotein complex. The hypoglycosylation reduces the ability of a-DG to bind laminin and other extracellular matrix ligands and is responsible for the pathogenesis of an inherited subset of muscular dystrophies known as the dystroglycanopathies. By exome and Sanger sequencing we identified two individuals affected by a dystroglycanopathy with mutations in b-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2). B3GALNT2 transfers N-acetyl galactosamine (GalNAc) in a b-1,3 linkage to N-acetyl glucosamine (GlcNAc). A subsequent study of a separate cohort of individuals identified recessive mutations in four additional cases that were all affected by dystroglycanopathy with structural brain involvement. We show that functional dystroglycan glycosylation was reduced in the fibroblasts and muscle (when available) of these individuals via flow cytometry, immunoblotting, and immunocytochemistry. B3GALNT2 localized to the endoplasmic reticulum, and this localization was perturbed by some of the missense mutations identified. Moreover, knockdown of b3galnt2 in zebrafish recapitulated the human congenital muscular dystrophy phenotype with reduced motility, brain abnormalities, and disordered muscle fibers with evidence of damage to both the myosepta and the sarcolemma. Functional dystroglycan glycosylation was also reduced in the b3galnt2 knockdown zebrafish embryos. Together these results demonstrate a role for B3GALNT2 in the glycosylation of a-DG and show that B3GALNT2 mutations can cause dystroglycanopathy with muscle and brain involvement.
Introduction
Congenital muscular dystrophies (CMDs) are a heterogeneous group of inherited diseases characterized by the onset of muscle weakness at birth or within 2 years of life and variable degrees of dystrophic changes on muscle biopsy. A common subgroup within the CMDs are the dystroglycanopathies, characterized by reduced functional glycosylation of a-dystroglycan (a-DG). The dystroglycan gene DAG1 (MIM 128239) encodes for a protein that is posttranslationally glycosylated and cleaved into two noncovalently associated proteins, a-DG and b-dystroglycan (b-DG).
1-3 a-DG is a peripheral membrane protein that binds to several extracellular matrix components, including laminin-a2 and other laminin-G domain containing ligands, 2, 4 and the transmembrane protein b-DG is anchored to the cytoskeleton by the dystrophin complex. 1 This connection helps to maintain structural integrity and force transmission between the cytoskeleton and the extracellular matrix but also allows for efficient signal transduction. The correct glycosylation of a-DG is essential for its function as an extracellular matrix receptor. 1 Dystroglycan is not restricted to skeletal muscle and is also present with varying degrees of glycosylation in many tissues such as the brain, peripheral nerve, and epithelia. 5, 6 In these tissues, dystroglycan has a multitude of functions including morphogenesis, early development, synaptogenesis, and signaling. 7 Dystroglycanopathies have been linked to mutations in 12 genes: Protein O-mannosyltransferase 1 8 [22] [23] [24] and is broadly related to the level of a-DG hypoglycosylation caused especially by mutations in some genes such as POMT1, POMT2, and POMGNT1 22 but less so with FKTN and FKRP, 22 as assessed with antibodies that specifically recognize glycosylated epitopes on a-DG. 17, 25, 26 In this report we describe the identification of mutations in b1,3-N-acetylgalactosaminyl transferase (B3GALNT2 [MIM 610194]) in individuals with dystroglycanopathy. The clinical severity ranges from severe WWS to milder dystroglycanopathy variants, invariably associated with brain involvement. Further analysis suggests that B3GALNT2 is involved in the functional glycosylation of a-DG.
Subjects and Methods

Subjects
This study covers two cohorts of affected individuals. The first cohort consisted of 47 dystroglycanopathy individuals 25 recruited at the Dubowitz Neuromuscular Centre at Great Ormond Street Hospital (London, UK). The second cohort consisted of 55 dystroglycanopathy individuals that were enrolled at Boston Children's Hospital (Boston, MA). All consents and local review board approvals were in accordance with the UK10K project ethical framework. Affected individuals P1 and P2 were identified from the UK cohort, and P3-P7 were identified from the USA cohort.
Exome and Sanger Sequencing
P1 was whole-exome sequenced as part of the UK10K project via the HiSeq platform (Illumina, San Diego, CA, USA) as paired-end 75 base pair (bp) reads. Sequencing, alignment of reads, and variant calling were performed as recently described. 18 
Skeletal Muscle Histology and Immunohistochemistry
Immunohistochemical studies were performed as described previously. 28 Unfixed frozen serial sections (7 mm) were incubated with primary antibodies for 1 hr, and then with the appropriate biotinylated secondary antibodies for 30 min followed by streptavidin conjugated to Alexa Fluor 594 (Life Technologies, Paisley, UK) for 15 min. Primary antibodies used were mouse monoclonal: a-DG IIH6 (clone IIH6C4 from K.P.C., 3, 29 ), b-DG (Leica, Milton Keynes, UK; clone 43DAG1/8D5), laminin-a2 (Merck Millipore, Nottingham, UK; catalog no. MAB1922 clone 5H2) to the 80 kDa C-terminal fragment, and goat polyclonal core a-dystroglycan GT20ADG. 30 Sections were evaluated with a Leica DMR microscope interfaced to MetaMorph (Molecular Devices, Sunnyvale, CA, USA).
Plasmid Construction and Mutagenesis
Human B3GALNT2 cDNA (Image clone: IRATp970G0734D) was obtained from Source Bioscience (Nottingham, UK). The coding sequence of B3GALNT2 was amplified with the primers listed in Table S1 (available online). Amplified products were cloned into the pcDNA3. Table S2 .
Flow Cytometry
Functional a-DG glycosylation was assessed in P1 and P2's fibroblasts with the a-DG antibody IIH6 (Merck Millipore). Fibroblasts were grown in DMEM (Life Technologies) containing 20% fetal bovine serum (FBS, PAA, Yeovil, UK), 2% glutamine, and 1% penicillin-streptavidin (Life Technologies) at 37 C with 5% CO 2 . The method was modified from Rojek et al. 31 Cells were detached with Accutase (Merck Millipore), centrifuged at 500 3 g for 3 min, and resuspended to a final density of 200,000 cells/ml. 
Immunoblot Analysis of Human Proteins
Immunoblotting of muscle protein lysate and fibroblast cell lysate was performed as previously described. 32, 33 The following anti- 
Knockdown of Zebrafish b3galnt2 and Characterization of the Phenotype
To determine the expression of zebrafish b3galnt2, we extracted RNA from 20-30 embryos with an RNeasy kit (QIAGEN, Crawley, UK), followed by reverse transcription with SuperScript III (Life Technologies). RT-PCR for b3galnt2 was done with RedTaq DNA polymerase kit (Sigma-Aldrich, Dorset, UK) with forward and reverse primers 5 0 -ACTCAGAGCTCCGCGATG-3 0 and 5 0 -CAGAG CAGAGATCCCTCAAA-3 0 , respectively.
Translation blocking (TB) (5 0 -CGCCGCCGCTGCACTTCTCAT GGAC-3 0 ) and splice blocking (SB) (5 0 -GGTCTGTCTGTCAAGGA GAAATAAA-3 0 ) morpholinos for b3galnt2 were obtained from Gene Tools, LLC (Philomath, OR, USA) and injected into 1-to 4-cell-stage Tuebingen Long Fin zebrafish embryos, which were reared as previously described. 34 Sequences of p53 and dag1 morpholinos have been described. 35, 36 Zebrafish expression plasmids (pCS2þ) containing b3galnt2 cDNA (Image clone: IRBOp991H0563D) and a C-terminal GFP tag were generated by Gateway Cloning Technology (Life Technologies) according to the manufacturer's instructions. mRNA for injection was made with mMessage mMachine SP6 kit (Ambion, for Life Technologies). Immunofluorescence staining by primary antibodies against laminin (L-9393, Sigma-Aldrich) and b-DG (Leica Microsystems) was performed on 48 hr postfertilization (hpf) whole-mount embryos as previously described. 35 For the Evans blue dye (EBD) assay, 48 hpf live embryos were immobilized in 1% low-melting-point agarose (Sigma-Aldrich) containing 0.016% tricaine (Sigma-Aldrich), and a solution of 0.1% EBD (Sigma-Aldrich) was injected into the pericardium. Two hours later, they were examined by confocal microscopy. Microsome preparation and immunoblot analysis of zebrafish proteins was performed as previously described. 19 
Results
B3GALNT2 Is Mutated in Individuals with Dystroglycanopathy
We diagnosed dystroglycanopathy in a single affected individual (P1). He presented at 4 months of age with developmental delay and a head circumference above 90 th percentile. All motor milestones were delayed due to axial hypotonia and increased limb tone due to spasticity; he never acquired independent walking. From the age of 6 years he could take steps with hands held and used a standing device to stand. He is a sociable boy, but his communication skills are mostly confined to sign language. His vision was also severely impaired due to marked myopia complicated by bilateral partial retinal detachment. A brain MRI showed cerebellar cysts, a thin corpus callosum, diffusely abnormal white matter signal on T2-weighted images, and cortical dysplasia in the form of frontoparietal polymicrogyria. The diagnosis was a dystroglycanopathy with clinical features overlapping MEB and FCMD. 25 Molecular genetic analysis of the genes previously associated with dystroglycanopathies was normal. We performed whole-exome sequencing on P1 and variant filtering left three genes with two potentially deleterious variants each. These were alanyl-tRNAsynthetase (AARS [MIM 601065]), nesprin-2 (SYNE2 [MIM 608442]), and b-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2). AARS mutations have been described to cause Charcot-Marie-Tooth disease, type 2N (MIM 613287), a phenotype not present in P1. SYNE2 variants have been associated with Emery-Dreifuss muscular dystrophy (MIM 612999), which is very distinct from P1's phenotype. B3GALNT2 (RefSeq accession number NM_152490.2) encodes for a glycosyltransferase that synthesizes the structure GlcNac-b1, 3GalNac, 37 a glycan that has previously been found on a-DG. 38, 39 Mutations in this gene could reduce the amount of functional a-DG glycosylation by preventing or impairing the formation of this particular glycan. P1 was compound heterozygous for the B3GALNT2 variants c.875G>C (p.Arg292Pro) and c.740G>A (p.Gly247Glu). We Sanger sequenced B3GALNT2 in the remaining UK cohort and found mutations in another individual of Turkish descent with a similar phenotype ( Table 1 ). This individual (P2) had a history of delayed gross motor skills and was unable to walk. His communication was limited, but his vision was intact. His brain MRI showed features similar to those of P1 ( Figure 1 ). For both P1 and P2, brain involvement was not detected in prenatal scans. Six additional mutations in B3GALNT2 were subsequently identified in four individuals by exome
The American Journal of Human Genetics 92, 1-12, March 7, 2013 3 sequencing (P3, P4, and P6) or by Sanger sequencing (P7) from a cohort with dystroglycanopathy and severe brain involvement. 40, 41 P3, P4, and P7 have at least one truncating mutation in B3GALNT2 and more severe clinical features than do P1 and P2 with evidence of severe hydrocephalus and cobblestone lissencephaly on brain MRI (Figure 1 ), leading to a diagnosis of WWS, the most severe form of dystroglycanopathy. P4 had two affected siblings: an affected female diagnosed with WWS (P5, for whom no DNA was available) and another affected sibling who was diagnosed prenatally with severe hydrocephalus and ocular malformations based on fetal ultrasound, leading to a pregnancy termination. The fetal DNA confirmed the presence of the compound heterozygous B3GALNT2 mutations identified in P4 and carried by the parents. P6 had a less severe presentation, with clinical and radiological features of dystroglycanopathy associated with abnormal white matter signal on T2-weighted MRI images.
All affected individuals had severe hypotonia and did not attain any motor milestones. P3, P4, and P5 also had epilepsy. See Table 2 for further clinical details and Figure S1 for a summary of the mutations found in P1-P4, P6, and P7.
Skeletal Muscle Biopsies of Individuals with B3GALNT2 Mutations Reveal Dystrophic Processes and Reduced a-DG Glycosylation A muscle biopsy of the quadriceps performed in P1 at 11 months of age showed features consistent with muscular dystrophy, including abnormal variation in fiber size, regenerating fibers, endomysial connective tissue, and internal nuclei. A muscle biopsy performed in P2 at 2 years of age showed less severe changes, with no obvious necrosis. Immunolabeling of laminin a2 with antibodies to the 80 and 300 kDa fragments showed a slight reduction of labeling of some fibers in P1 but was normal in P2 (data not shown). Labeling of a-DG with IIH6 was variably reduced whereas labeling of b-DG, of core a-DG (Figure 2) , and of laminin chains a5, b1, and g1 was normal (data not shown).
Immunoblotting for a-DG with the IIH6 antibody in muscle protein lysates showed a profound reduction in a-DG functional glycosylation for P1 and a mild reduction with a lower molecular weight for P2. There was no change in the amount of b-DG (Figure 3 ). Immunoblotting for IIH6 in fibroblasts of both P1 and P2 showed a severe reduction in the IIH6 epitope ( Figure S2 ).
Affected Fibroblasts with Mutations in B3GALNT2
Have Reduced a-DG Glycosylation Flow cytometry was used to assess the level of functional a-DG glycosylation in P1 and P2 fibroblasts compared to Figure 2 . Functional a-DG Glycosylation Is Reduced in Individuals with B3GALNT2 Mutations An examination of skeletal muscle cryosections from control, P1, and P2 revealed that glycosylated a-DG is reduced in individuals with B3GALNT2 mutations (P1 and P2) whereas b-DG was well preserved. Staining with the GT20ADG antibody against the core a-DG protein showed that the core was better preserved in P2 than in P1 as some variability was seen among the fibers. Flow cytometry showed that P1 and P2 fibroblasts were reduced in functionally glycosylated a-DG compared to the two controls (p < 0.05). The controls had 75.28 average and 79.98 mean fluorescence intensity (MFI), whereas B3GALNT2 fibroblasts have 33.53 average MFI (P1) and 28.5 average MFI (P2), suggesting a profound reduction of the IIH6 epitope ( Figure 3 ; Table S3 ).
To further validate this technique, in addition to the nonpathological fibroblast controls, we also tested fibroblasts from an individual with a ryanodine receptor mutation (RYR1 [MIM 180901]) and from an individual with an a-glucosidase mutation (GAA [MIM 232300]). These fibroblasts all had MFI values that were not statistically different than the controls listed above (Table S3) . Additionally, two individuals carrying mutations in two genes previously associated with dystroglycanopathy (POMT1 and FKRP) had significantly (p < 0.05) reduced MFI values compared to both the nonpathological and the pathological controls described here (Table S3) .
B3GALNT2 Localizes to the Endoplasmic Reticulum and This Localization Is Disrupted by Dystroglycanopathy Mutations
In order to assess the functional effect of the B3GALNT2 mutations, we examined the localization of the wild-type and mutant proteins. Wild-type B3GALNT2 colocalized with the ER-specific marker ERp72 (Figure 4) , suggesting B3GALNT2 localization to the ER despite the absence of an obvious ER retention signal. Like wild-type, the c.875G>C (p.Arg292Pro) mutant colocalized with the ER marker, indicating that this mutation did not alter the protein localization (Figure 4) . However, both c.740G>A (p.Gly247Glu) and c.802G>A (p.Val268Met) mutants had diffuse localization compared to wild-type and the ER marker (Figure 4) , suggesting that these mutations disrupt the ER localization of B3GALNT2.
Knockdown of Zebrafish b3galnt2 Recapitulates Several Aspects of the Human Phenotypes Including Reduced a-DG Glycosylation
To analyze the role of B3GALNT2 in vivo, we used zebrafish as a vertebrate model. Human B3GALNT2 has a single ortholog in zebrafish (Ensembl ID ENSDARG00000046133). Zebrafish B3galnt2 is 53% identical to human B3GALNT2 and the amino acid sequence of the galactosyltransferase domain alone is conserved with 68.5% identity. Publically available in situ hybridization data indicate that b3galnt2 is ubiquitously expressed at early stages of zebrafish development, becoming more anteriorly localized as development progresses (ZFIN database). By using RT-PCR, we confirmed that b3galnt2 expression was detectable throughout early development ( Figure S3 ).
To knock down b3galnt2 in zebrafish embryos, we injected a translation-blocking (TB) morpholino (4 ng) together with a p53 morpholino (2 ng) to reduce p53-mediated off-target effects. 42, 43 Under confocal microscopy, we showed that the expression of GFP-tagged B3galnt2 was effectively suppressed, confirming the morpholino specificity ( Figure 5 ). Zebrafish b3galnt2 knockdown embryos (morphants) showed curved body, mild retinal degeneration, and severely impaired motility ( Figure 5 ). Similar to fktn, fkrp, and ispd morphants,
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b3galnt2 morphants recapitulated the hydrocephalus phenotype present in P3, P4, and P7. To further confirm the morpholino specificity, we injected a b3galnt2 spliceblocking morpholino, which also caused very similar phenotypes (data not shown).
To characterize the muscle phenotype, we performed immunofluorescence staining. Compared to the V-shaped somite boundaries flanking straight muscle fibers in wildtype embryos, b3galnt2 morphants consistently showed slightly U-shaped somites and disordered muscle fibers ( Figure 5 ). Laminin staining revealed occasional gaps in the myosepta (the connective tissues where the muscle fibers anchor), suggesting disruption of the extracellular matrix ( Figure 5 ). Next, we quantified the severity of muscle damage by Evans blue dye (EBD) assay. 44 EBD penetrates compromised sarcolemma or accumulates at lesions in muscle. Compared to wild-type embryos, b3galnt2 morphants showed more severely damaged muscle with increased number of lesions, ranging from less than 10 to more than 30 lesions per embryo ( Figure 5 ). Immunoblot analysis with the IIH6 antibody on protein extracts from wild-type embryos and b3galnt2 morphants showed a reduction of the IIH6 signal in b3galnt2 morphants, indicating that knockdown of b3galnt2 led to reduced functional glycosylation of a-DG. This is consistent with the human data and strongly suggests that this may be the molecular mechanism behind the phenotypes described. 
Discussion
In this study we describe the use of exome and Sanger sequencing for the identification of mutations in B3GALNT2 in six dystroglycanopathy-affected families characterized by the invariable presence of structural brain involvement and, in some severe cases, ocular involvement. The spectrum of severity in individuals with (D) Evans blue dye assay (EBD) highlights frequent lesions between muscle fibers in b3galnt2 morphants, which are very rarely seen in wild-type embryos (the same image is shown with and without DIC microscopy). (A-D) b3galnt2 MO: b3galnt2 TB morpholino (4 ng) coinjected with p53 TB morpholino (2 ng). Scale bars represent 50 mm. (E) Immunoblotting by isolated microsome protein from 48 hpf embryos and IIH6 antibody showed a reduction in glycosylated a-DG in the b3galnt2 knockdown embryos. b3galnt2 MO: b3galnt2 TB morpholino (5 ng) coinjected with p53 TB morpholino (2.5 ng). dag1 MO: dag1 TB morpholino (5 ng).
B3GALNT2 mutations ranged from severe WWS to mild MEB-like or FCMD-like conditions 45 (Tables 1 and 2 (Figure 4) . The missense mutation (c.875G>C [p.Arg292Pro]) showed no obvious changes in localization compared to wild-type (Figure 4 ), but this amino acid is highly conserved in vertebrates (Figure 6 ), so it is likely to be of functional importance. To determine whether mutations in B3GALNT2 led to a reduction in the level of functional a-DG glycosylation, we assessed the muscle and fibroblasts of P1 and P2 by muscle immunohistochemistry (Figure 2 ), flow cytometry, and immunoblotting (Figures 3 and S2) . Although each technique revealed some degree of hypoglycosylation, the fact that flow cytometry and immunoblotting of the fibroblasts indicated a more severe depletion compared to the immunoblot of muscle protein lysate may be related to tissue-specific glycosylation of a-DG. 5, 6, 46 Knockdown of zebrafish b3galnt2 recapitulated aspects of the human phenotype including dystrophic muscle, hydrocephalus, and reduced functional a-DG glycosylation. The myotomal lesions revealed by EBD ( Figure 5 ) are very similar to the phenotype caused by knockdown of other known dystroglycanopathy genes including FKTN and FKRP. 1 These mannose residues can themselves be modified. For example, a b1,2 linked N-acetyl glucosamine (GlcNAc) group can be added by POMGNT1 38 or a b1,4
linked GlcNAc group can be added by an unknown GlcNAc transferase. 38 We speculate that after the addition of b1,4
linked GlcNAc, B3GALNT2 completes the trisaccharide GalNAc-b1,3-GlcNAc-b1,4-Man. 38, 39 This trisaccharide is believed to contain a LARGE-dependent 6-O-phosphoryl modification on the mannose residue 38 and is required for ligand binding glycan of a-DG. 37 There may be other protein targets of B3GALNT2, which are currently unknown. 37 We propose that the phosphorylated trisaccharide is produced in the endoplasmic reticulum, as suggested by the subcellular localization of B3GALNT2.
Although O-mannosylation occurs in the ER and O-GalNAcylation in the Golgi, it has been recently suggested that certain GalNAc glycosyltransferases can be located in the ER, 47 which appears to be the case for B3GALNT2.
Although further study is needed to establish the precise role of B3GALNT2 in the glycosylation of a-DG, our data show that mutations in B3GALNT2 can cause dystroglycanopathy. Furthermore, this study provides insight into the complexity of a-DG glycoslyation and illustrates the utility of whole-exome sequencing with functional analysis for the identification of mutations that cause dystroglycanopathies. Additional genetic discoveries will help to complete the understanding of a-DG glycosylation as well as elucidate the pathological mechanisms underlying the muscle and brain phenotypes associated with these diseases.
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